According to Zhitong Finance APP, Henlius Biotech (HKEX: 02696) rose nearly 6%, up 5.83% as of press time to HK$58.95, with a turnover of HK$41.6221 million.

On the news front, the 2026 European Society for Medical Oncology (ESMO) Annual Meeting will be held in Madrid, Spain, from October 23 to 27. During this year's congress, Henlius Biotech will present data from 12 studies, covering core oncology pipeline products including the anti-PD-1 monoclonal antibody H drug Hansizhuang®, the PD-L1 ADC HLX43, and the innovative small-molecule CDK4/6 inhibitor Futoning®, focusing on the latest advances and proof-of-concept results in high-incidence cancers such as lung cancer, gastrointestinal tumors, and breast cancer.

Among them, data from the bridging trial HLX10-005-SCLC301E (ASTRIDE study) conducted in the United States for the independently developed H drug Hansizhuang® will be read out for the first time in the form of a Proffered Paper oral presentation.

China Post Securities noted that the company's biosimilar business is driven by both domestic and overseas markets, and its PD-1 has partnered with multiple overseas giants to go global, providing stable cash flow for innovative R&D. The company's innovative pipelines HLX43 and HLX22 demonstrate potentially best-in-class competitiveness and are embracing overseas expansion opportunities, with the potential to open up the global market. The company has laid out multiple early-stage pipelines with global competitiveness in frontier technology areas such as TCE and bispecific ADCs, including HLX3901 (tetraspecific) and HLX3902 (trispecific), injecting strong momentum into long-term development.